Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Control Groups × Genitourinary × Clear all

Phase

Phase NA 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Castration-resistant Prostate Cancer 1

Interventions

pembrolizumab 59 Docetaxel 43 Nivolumab 39 Prednisone 27 enzalutamide 25 Gemcitabine 21 Cyclophosphamide 18 Paclitaxel 17 Radiotherapy 16 Ipilimumab 14 Cisplatin 14 Carboplatin 14 Abiraterone Acetate 13 aldesleukin 12 fludarabine 11 atezolizumab 11 Pluvicto 11 Interleukin-2 11 Filgrastim 11 Bevacizumab 11 avelumab 10 Magnetic Resonance Spectroscopy 10 Everolimus 10 gallium 68 PSMA-11 9 fludarabine phosphate 9 durvalumab 9 enfortumab vedotin 8 cemiplimab 8 cabozantinib 8 Sunitinib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05549778 2023-07-11

PEACe

Jiangnan University

Phase 1/2 Completed

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡